| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6797381 | Journal of the American Academy of Child & Adolescent Psychiatry | 2014 | 14 Pages |
Abstract
Short-term ATX treatment is safe and superior to placebo for overall ADHD symptoms and key secondary outcomes, with a medium ES. However, a relevant patient subgroup (40%) continues to have significant symptomatology, requiring additional clinical attention.
Related Topics
Health Sciences
Medicine and Dentistry
Perinatology, Pediatrics and Child Health
Authors
Shimon MD, Christoph U. MD,